Australia markets open in 5 hours 26 minutes

Tonix Pharmaceuticals Holding Corp (TPM0.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
1.73000.0000 (0.00%)
As of 07:02AM CET. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

    CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m. ET in New York City. Investors interested in arranging a meeting with the Company’s managemen

  • GlobeNewswire

    New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

    New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT Episode 556: 1). Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) 2). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 3). Dynex (CRYPTO: DNX) ($DNX) 4). "Bitdeer Technology Group, Inc. (NASDAQ: BTDR) ($BTDR) & Sustainable Bitcoin Protocol 5). BlackStar Enterprise Group, Inc. (OTCPINK: BEGI) ($BEGI) -www.newtothestreet.com NEW YORK, Feb. 16,

  • GlobeNewswire

    Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

    Clinical results show that Tonyma™ has broad-spectrum activity, addressing the three core fibromyalgia symptoms: pain, fatigue, and sleep disturbance Tonmya™ has a favorable tolerability profile well-suited for chronic treatment CHATHAM, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the